GlassScriptPhysician profile
Dennis Hilliard
NPI 1659355691
$14,521.00
in general payments reported to CMS, 2019-2025
82 companies · $934 in 2025
The $934 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,832 · 2020: $2,039 · 2021: $2,452 · 2022: $2,147 · 2023: $1,989 · 2024: $2,128 · 2025: $934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,032 · Education: $18.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,031.75 |
| Education | $18.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,243.64 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,040.27 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Astrazeneca Pharmaceuticals LP | $1,022.18 | 2019-2025 | Calquence, Enhertu, Tagrisso |
| Merck Sharp & Dohme LLC | $824.06 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $761.34 | 2019-2025 | Darzalex, Imbruvica, Tecvayli |
| Celgene Corporation | $681.61 | 2019-2025 | Pomalyst, Reblozyl, Pomalyst |
| Beigene USA, INC. | $571.32 | 2020-2025 | Brukinsa |
| Genzyme Corporation | $539.60 | 2019-2023 | |
| Pfizer INC. | $472.02 | 2019-2025 | |
| Amgen INC. | $428.15 | 2019-2023 | Kyprolis |
| Pharmacyclics LLC, An Abbvie Company | $414.73 | 2019-2023 | Imbruvica |
| Genentech USA, INC. | $385.86 | 2019-2025 | Venclexta, Tecentriq |
| Astellas Pharma US INC | $384.50 | 2019-2025 | Vyloy, Padcev |
| Glaxosmithkline, LLC. | $337.03 | 2020-2025 | Zejula, Ojjaara, Jemperli |
| Gilead Sciences, INC. | $267.18 | 2019-2025 | Trodelvy |
Show all 82 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Hilliard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.